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The Editorial on the Research Topic 
Current Challenges in Immune and Other Acquired Cytopenias of Childhood
Chronic immune thrombocytopenia (ITP), Evans syndrome (ES), aplastic anemia, etc., are descriptive 
terms for immune-mediated cytopenias in pediatric hematology that may be summarized as a group 
of disorders of immune dysregulation based on ill-defined poly- and epigenetic diatheses toward 
autoimmunity and monogenic primary immunodeficiencies (PIDs); a growing number of which is 
being identified with next-generation sequencing technologies. The historical view, that cytopenia in 
the context of these diseases is “acquired,” “idiopathic,” or termed “primary” because cytopenia may 
be the first and only manifestation at early age, is challenged by the emerging recognition of underly-
ing pathomechanisms and predispositions. Similarly, patients with congenital bone marrow failure 
syndromes may present without previous syndromic features later during childhood or adolescence 
and contribute to the wide spectrum of differential diagnosis of cytopenia in childhood. In addition 
to the diagnostic complexity and prognostic uncertainty, the therapeutic approach to patients with 
these conditions remains undetermined in many situations. In severe cases, allogeneic hematopoietic 
stem cell transplantation may be the option of choice; other conditions might require temporary 
immunosuppression or even no treatment at all. Although the indication for stem cell transplantation 
will always predominantly depend on the clinical course and status of a patient, the definition of a 
clear-cut pathomechanism potentially offers a guidance toward targeted therapy approaches.
Autoimmunity and cytopenias may occur in the context of many types of PID, whether 
belonging to the combined immunodeficiencies, to those with predominant antibody deficiency, 
to syndromic PIDs (e.g., Wiskott–Aldrich or 22q11 deletion syndrome), to the category of PIDs 
with immune dysregulation [e.g., autoimmune lymphoproliferative syndrome (ALPS), immune 
dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome], as well as to 
humoral and cellular defects of the innate immune system (1, 2). In addition to classical PIDs 
highly associated with autoimmunity and autoimmune cytopenias such as ALPS or common vari-
able immunodeficiency (CVID), an increasing number of PID syndromes have been described 
recently to be associated with immune dysregulation and symptoms of autoimmunity such as 
immune cytopenia. The phenotype in 9 of 13 newly discovered monogenic PIDs published within 
the last year include cytopenia, immune dysregulation, autoimmunity, and/or autoinflammation 
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as their main manifestation (1, 3, 4), adding to at least 8 of 19 
novel PIDs the year before [(5); Al-Herz et al.]. Yet, this fact has 
not universally been translated into the diagnostic work-up of 
cytopenia in childhood.
The present research topic on immune and other acquired 
cytopenias of childhood at Frontiers in Pediatric Hematology 
and Immunology encompasses reviews, original studies, and 
single-case observations as well as management strategy papers 
that address the current challenge how to deal with these 
disorders. Erlacher and Strahm review in depth aspects and 
differential diagnosis of pancytopenia in childhood, ranging 
from inherited bone marrow failure syndromes to extrinsically 
acquired (e.g., infection-associated) defects of hematopoiesis; 
from autoimmunity to hemophagocytic syndromes and malig-
nancies (e.g., acute lymphoblastic leukemia and myelodysplas-
tic syndromes).
Classical inherited bone marrow failure syndromes, e.g., 
Fanconi anemia, Dyskeratosis congenita, Shwachman Bodian 
Diamond Syndrome, and Diamond Blackfan anemia, are based 
on defects of  DNA and telomere maintenance or ribosome 
function. However, immune dysregulation and autoimmun-
ity often have a rather unclear and heterogenous etiology. 
Polygenetic defects or polymorphisms as well as an array of 
environmental factors are known to contribute to a predisposi-
tion to autoimmunity. In susceptible individuals, autoantibodies 
may be produced secondarily to infections or other exogenous 
triggers due to cross-reactivity (molecular mimicry). Pathologic 
processing of cell debris can lead to presentation of self-antigens 
to the immune system like anti-glycoprotein IIa/IIIb antibod-
ies in ITP or anti-double strand DNA antibodies in systemic 
lupus erythematosus (SLE). Among several PID disorders that 
lead to a predisposition toward autoimmunity, ALPS, most 
often due to defective Fas-mediated lymphocyte apoptosis and 
impaired T cell maturation, is a classical PID leading to autoim-
mune cytopenia, splenomegaly, and lymphoproliferation, with 
splenic sequestration sometimes contributing to cytopenia. 
Furthermore, the heterogeneous group of CVID is highly associ-
ated with autoimmune cytopenia due to autoantibody formation 
based on defective B cell selection and maturation. CVID and 
ALPS may be ruled out on the basis of relatively routine basic 
immunological tests. The large group of combined immuno-
deficiencies is generally associated with a lack of naive T cells 
and an oligoclonal T cell repertoire, which predisposes these 
patients to autoimmunity in addition to infections. Wiskott–
Aldrich and 22q11 deletion syndromes are linked to defective 
regulatory T (Treg) cells and impaired T cell development, and 
may be excluded by detection of additional clinical syndromic 
features, other routine laboratory parameters, impaired in vitro 
lymphocyte proliferation, and molecular genetic tests; whereas 
patients with IPEX-(like) syndromes have a primary Treg 
defect and most often present with enteropathy,  multi-organ 
autoimmunity, and show reduced or absent Treg cell function 
and diminished STAT5 phosphorylation. Recently, homozygous 
loss-of-function mutations in the LRBA gene (3, 6, 7) as well as 
haploinsufficiency of CTLA-4 (8, 9) gain-of-function of PI-3-
kinase (10, 11) or of STAT3 (12, 13) showed in part ALPS-like 
phenotypes with autoimmune cytopenias. In line with these 
observations, an increasing number of patients with autoim-
munity including cytopenias will be referred to genetic analysis 
to find new causative genes. Rao highlights the experience of 
the NIH with one of the largest ALPS cohorts in the world, 
emphasizing the need of effective immune suppression. One 
of the main lessons from the past decades taught us to avoid 
splenectomy. Furthermore, Aladjidi et al. report the results from 
French OBS’CEREVANCE, an observational cohort gathering 
data on children with ES, chronic ITP and autoimmune hemo-
lytic anemia (AIHA). One hundred fifty-six patients with ES 
were analyzed; interestingly, in 13 patients SLE was diagnosed, 
but ALPS was diagnosed only in 3 patients. Thirty percent of all 
patients were classified as “primary” forms because cytopenia 
remained the only symptom; in 60% of the patients, the authors 
observed additional clinical or biochemical features to term 
this fraction as “unclassified” (Aladjidi et  al.). One major red 
flag for pediatricians: 10% of all patients died at a median age 
of 14.3  years either due to hemorrhage or infections with the 
unknown participating role of immunosuppressive treatment. 
Thus, a “wait-and-see” strategy in ES seems not to be justified 
for a long period.
Phenotypic variations of diseases linked to (pan-)cytopenia 
are shown in the case report of Karastaneva et al. Two unrelated 
patients with Fanconi anemia developed rather untypical ITP, 
but showing a normal marrow. Management of ITP was accom-
plished with intravenous immunoglobulins (IVIG) and danazol. 
This rather simple and non-toxic ITP treatment warrants evalu-
ation of autoimmune phenomena in other bone marrow failure 
syndromes.
Although in most patients with ITP first-line treatment usu-
ally leads to remission, the application of thrombopoietin ago-
nist is warranted in patients with refractory and chronic forms 
of ITP. Garzon and Mitchell review the use of Eltrombopag and 
Romiplostim, which depicts a change in treatment paradigm, as 
an immunosuppressive regime is avoided, and these drugs are 
well tolerated. Finally, Koster et  al. report the experience of a 
single hematooncological unit with two cases of a rare infectious 
disease, namely Leishmaniosis that led to severe cytopenia. The 
reported incidence of Leishmaniosis among pediatric patients 
with cytopenia is extremely low, having said that the experience 
of the reporting hematooncologial unit in central Germany 
with two cases in 10 years shows how coincidental rare events 
might happen. Hemophagocytosis (detected after repeated 
marrow puncture) and polyclonal B cell activation (false posi-
tive antibodies for other infectious diseases) are hallmarks of 
Leishmaniosis.
This research topic has collected a range of contributions 
focusing on diagnostic and therapeutic challenges, reaching 
from scientific progress in the immunological and hematological 
context of cytopenias to clinical challenges such as the experi-
ence with novel treatment approaches and lessons from patient 
registries. Despite tremendous progress has been made with 
next-generation sequencing techniques applied in the diagnostic 
work-up and the availability of novel potent immunosuppressive 
drugs and hematopoiesis stimulating agents for the treatment 
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